Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04370301 |
|
Recruitment Status :
Recruiting
First Posted : April 30, 2020
Last Update Posted : January 12, 2021
|
Sponsor:
Fred Hutchinson Cancer Research Center
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase II trial studies the outcomes of using a JAK inhibitor prior to reduced intensity haploidentical (Haplo) transplantation for the treatment of primary or secondary myelofibrosis (MF). Haplo transplant has been shown to be safe and effective in patients with leukemia and lymphoma who don't have an available sibling donor. The primary risk of using Haplo HCT in patients with MF is graft failure as the graft failure rate has been historically higher with Haplo HCT than with other donor sources and higher with MF patients due to bone marrow fibrosis than in patients with other hematologic malignancies. JAK inhibitors when used in patients with MF may decrease the size of the spleen and decrease inflammation in the bone marrow. Therefore using a JAK inhibitor prior to Haplo transplant has the potential to decrease graft failure in patients with MF. Haplo transplants for patients with MF have been done successfully at multiple institutions in patients not on a study and are currently being covered by Medicare.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Primary Myelofibrosis Secondary Myelofibrosis | Drug: Cyclophosphamide Drug: JAK Inhibitor Drug: Fludarabine Biological: Recombinant Granulocyte Colony-Stimulating Factor Drug: Melphalan Drug: Mycophenolate Mofetil Procedure: Peripheral Blood Stem Cell Transplantation Drug: Tacrolimus Radiation: Total-Body Irradiation | Phase 2 |
OUTLINE:
JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of hematopoietic cell transplantation (HCT) conditioning through day -4 before transplantation.
CONDITIONING: Patients receive melphalan intravenously (IV) over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo total-body irradiation (TBI) on day -1.
TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.
GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then orally (PO) for 6 months, mycophenolate mofetil PO twice daily (BID) or three times daily (TID) beginning day 5 for 6 weeks, and granulocyte colony-stimulating factor (G-CSF) subcutaneously (SC) beginning day 7 until neutrophil recovery is > 1,500/mm^3.
After completion of study treatment, patients are followed up between day 80-100, at 1 year, and then up to 5 years.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 10 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis |
| Estimated Study Start Date : | February 11, 2021 |
| Estimated Primary Completion Date : | August 31, 2023 |
| Estimated Study Completion Date : | August 31, 2028 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Primary myelofibrosis
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)
JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation. CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1. TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0. GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is > 1,500/mm^3. |
Drug: Cyclophosphamide
Given IV
Other Names:
Drug: JAK Inhibitor Given PO
Other Names:
Drug: Fludarabine Given IV
Other Name: Fluradosa Biological: Recombinant Granulocyte Colony-Stimulating Factor Given SC
Other Names:
Drug: Melphalan Given IV
Other Names:
Drug: Mycophenolate Mofetil Given PO
Other Names:
Procedure: Peripheral Blood Stem Cell Transplantation Given IV
Other Names:
Drug: Tacrolimus Given IV and PO
Other Names:
Radiation: Total-Body Irradiation Undergo TBI
Other Names:
|
Primary Outcome Measures :
- Probability of primary and secondary graft failure [ Time Frame: Up to 3 years ]
Secondary Outcome Measures :
- Incidence of severe (grade 3 or 4) cytokine release syndrome [ Time Frame: Up to 3 years ]
- Non-relapse mortality (NRM) [ Time Frame: Day 100 ]
- NRM [ Time Frame: 1 year ]
- Overall survival [ Time Frame: 1 year ]
- Overall survival [ Time Frame: 3 years ]
- Incidence and severity of acute and chronic graft versus host disease (GVHD) [ Time Frame: Up to 3 years ]
- Incidence of relapse [ Time Frame: At 1 year ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- PART 1: JAK INHIBITOR ADMINISTRATION INCLUSION CRITERIA
- Diagnosis of primary myelofibrosis (PMF) as defined by the 2016 World Health Organization classification system or diagnosis of secondary MF as defined by the International Working Group (IWG) for Myeloproliferative Neoplasms Research and Treatment criteria
- Patients meeting the criteria for intermediate-1, intermediate-2 or high-risk disease by the Dynamic International Prognostic Scoring System (DIPSS)-plus scoring system (DIPSS may be used if all data from DIPSS are not available)
- Ability to understand and the willingness to sign a written informed consent document
- Patient must be a potential hematopoietic stem cell transplant candidate
- PART 2: ALLOGENEIC STEM CELL TRANSPLANT INCLUSION CRITERIA
- Meeting criteria for 1st phase as above, at time of initiation of JAK inhibitor, including ability to understand and willingness to sign a written informed consent. Patients arriving to our institution for transplant and not enrolled in Part 1 may still be enrolled in Part 2 if Part 1 criteria met. These patients will have Part 1 endpoints transcribed from medical records
- Received JAK inhibitor for at least 8 weeks immediately prior to conditioning and be able to continue until day -4 pre-transplant
- Karnofsky performance status score >= 70
- Calculated creatinine clearance using the Cockcroft-Gault formula or 24 hour (hr) urine creatinine clearance must be > 60 ml/min
- Total serum bilirubin must be < 3 mg/dL unless the elevation is thought to be due to Gilbert's disease or hemolysis
- Transaminases must be < 3 x the upper limit of normal
- Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension. Patients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will be excluded
- Diffusion capacity of the lung for carbon monoxide (DLCO) corrected > 60% normal; may not be on supplemental oxygen
- Left ventricular ejection fraction > 40% OR shortening fraction > 26%
- Comorbidity Index < 5 at the time of pre-transplant evaluation
- DONOR: Patients must be screened prior to transplant for donor-specific anti-HLA antibodies (DSA). Patients with DSA will be reviewed by the principal investigator and considered for desensitization treatment
- DONOR: Children are preferred over siblings and parents
- DONOR: Younger donors are preferred over older donors
- DONOR: ABO matched donors are preferred over minor ABO mismatched and over major ABO mismatch donors
Exclusion Criteria:
- PART 1: JAK INHIBITOR ADMINISTRATION EXCLUSION CRITERIA
-
Contraindication to receiving a JAK inhibitor including:
- Patients who have known hypersensitivity to JAK inhibitors
- Clinical or laboratory evidence of significant renal or hepatic impairment including cirrhosis
- Active uncontrolled infection
- Known human immunodeficiency virus (HIV) positivity
- Women who are pregnant or trying to conceive
- Caution should be used in patients with platelets < 100 though adjustments in dose can be made to accommodate anyone with platelets > 50
- History of prior allogeneic transplant
- Leukemic transformation (> 20% blasts)
- PART 2: ALLOGENEIC STEM CELL TRANSPLANT EXCLUSION CRITERIA
- Uncontrolled viral or bacterial infection at the time of study enrollment
- Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval
- Known HIV positivity
- Pregnant or breastfeeding
- Availability of an human leukocyte antigen (HLA)-identical or 1-allele-mismatched related donor or an HLA 10 of 10 matched unrelated donor
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04370301
Contacts
| Contact: Rachel Salit | 206-667-1317 | rsalit@fredhutch.org |
Locations
| United States, Washington | |
| Fred Hutch/University of Washington Cancer Consortium | Recruiting |
| Seattle, Washington, United States, 98109 | |
| Contact: Rachel B. Salit 206-667-1317 rsalit@fredhutch.org | |
| Principal Investigator: Rachel B. Salit | |
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Rachel B Salit | Fred Hutch/University of Washington Cancer Consortium |
| Responsible Party: | Fred Hutchinson Cancer Research Center |
| ClinicalTrials.gov Identifier: | NCT04370301 |
| Other Study ID Numbers: |
RG1006957 NCI-2020-02422 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 10441 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium ) P30CA015704 ( U.S. NIH Grant/Contract ) |
| First Posted: | April 30, 2020 Key Record Dates |
| Last Update Posted: | January 12, 2021 |
| Last Verified: | September 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Neoplasm Metastasis Primary Myelofibrosis Neoplastic Processes Neoplasms Pathologic Processes Myeloproliferative Disorders Bone Marrow Diseases Hematologic Diseases Mycophenolic Acid Cyclophosphamide Melphalan Mechlorethamine Nitrogen Mustard Compounds Fludarabine Tacrolimus |
Sargramostim Lenograstim Janus Kinase Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Calcineurin Inhibitors Enzyme Inhibitors Antibiotics, Antineoplastic |